Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 15/20 | 0.57 |
| ▸ | KDM4C | Q9H3R0 | 14/20 | 0.57 |
| ▸ | PHF8 | Q9UPP1 | 5/20 | 0.54 |
| ▸ | KDM4A | O75164 | 4/20 | 0.54 |
| ▸ | KDM5C | P41229 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518306 | 0.79 | KDM4C (0.50) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL8337243 | 0.79 | ALDH1A1 (0.54) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL14944834 | 0.77 | KDM4C (0.43) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL7082287 | 0.77 | KDM4C (0.43) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL5520907 | 0.74 | KDM5A (0.51) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL14064830 | 0.71 | GGPS1 (0.47) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL14944840 | 0.70 | KDM4A (0.58) | KDM5AKDM4CPHF8KDM4AALDH1A1 | |
| SCHEMBL23260326 | 0.69 | KDM5A (0.54) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL21389643 | 0.69 | KDM5A (0.56) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL16745734 | 0.69 | KDM5A (0.47) | KDM5AKDM4CPHF8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | KDM5A 15/4885KDM4C 20/4885PHF8 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.